You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

CLARISCAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Clariscan, and when can generic versions of Clariscan launch?

Clariscan is a drug marketed by Ge Healthcare and is included in one NDA.

The generic ingredient in CLARISCAN is gadoterate meglumine. Four suppliers are listed for this compound. Additional details are available on the gadoterate meglumine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Clariscan

A generic version of CLARISCAN was approved as gadoterate meglumine by HENGRUI PHARMA on April 11th, 2022.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CLARISCAN?
  • What are the global sales for CLARISCAN?
  • What is Average Wholesale Price for CLARISCAN?
Summary for CLARISCAN
Drug patent expirations by year for CLARISCAN
Drug Prices for CLARISCAN

See drug prices for CLARISCAN

Pharmacology for CLARISCAN

US Patents and Regulatory Information for CLARISCAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare CLARISCAN gadoterate meglumine SOLUTION;INTRAVENOUS 210016-005 Nov 24, 2020 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ge Healthcare CLARISCAN gadoterate meglumine SOLUTION;INTRAVENOUS 210016-003 Nov 1, 2019 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ge Healthcare CLARISCAN gadoterate meglumine SOLUTION;INTRAVENOUS 210016-001 Nov 1, 2019 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ge Healthcare CLARISCAN gadoterate meglumine SOLUTION;INTRAVENOUS 210016-002 Nov 1, 2019 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ge Healthcare CLARISCAN gadoterate meglumine SOLUTION;INTRAVENOUS 210016-004 Aug 4, 2020 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.